Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey

Prevalence of gallbladder disease among persons with hepatitis C virus infection in the United States

Although cirrhosis is a known risk factor for gallstones, little is known about gallbladder disease (GBD) in individuals with hepatitis C virus (HCV) infection. We determined the association between chronic HCV infection and GBD in a representative sample of adults in the United States. Data on HCV infection and GBD were available for 13,465 persons 20 to 74 years of age who participated in the Third National Health and Nutrition Examination Survey. The presence of GBD (gallstones or cholecystectomy) was determined using abdominal ultrasonography, and HCV infection was assessed via a positive HCV antibody test and a positive HCV RNA test. Overall, 1.6% of adults (95% CI, 1.1-2.1) had chronic HCV infection and 12.5% (95% CI, 11.3-13.7) had GBD. After adjusting for potential confounding variables, the odds of gallstones (OR = 3.20; 95% CI, 1.08-9.45) and cholecystectomy (OR = 4.57; 95% CI, 1.57-13.27) among HCV-positive men was significantly higher compared with HCV-negative men. In contrast, the adjusted odds of gallstones (OR = 2.55; 95% CI, 0.58-11.25) and cholecystectomy (OR = 0.70; 95% CI, 0.21-2.37) among HCV-positive women was not significantly higher. The odds of GBD increased significantly with the severity of liver disease as assessed via elevated serum bilirubin levels and low levels of serum albumin and platelets. In conclusion, chronic HCV infection was strongly associated with GBD among men but not women in the United States, and GBD was more common in adults with severe liver disease.

Endoscopic stent insertion into the gallbladder for symptomatic gallbladder disease in patients with end-stage liver disease

BACKGROUND

Endoscopic stent insertion into the gallbladder entails placement of a double-pigtail polyethylene stent between the gallbladder and the duodenum at ERCP. This procedure may be an effective temporary measure in patients with severe comorbid conditions, especially end-stage liver disease, that subsequently allows more definitive therapy, including liver transplantation.

METHODS

The records for 29 patients who underwent attempted endoscopic gallbladder stent insertion between May 1999 and May 2004 were reviewed retrospectively.

RESULTS

Mean patient age was 47 years; 86% of the patients were listed for liver transplantation, with a mean model for end-stage liver disease score of 15; 72% had Child's class B cirrhosis. Indications for gallbladder stent placement included recurrent biliary colic (69%), acute cholecystitis (17%), acalculous cholecystitis (7%), and gallstone pancreatitis (7%). Of the 29 patients who underwent ERCP, stent placement was successful in 26 (90%). Median follow-up was 9.4 months (range 0.1-40.5 months). Of those who had a stent placed, 6 (22%) subsequently underwent liver transplantation and another 15 (56%) were alive, most awaiting liver transplantation. Only 3 patients had late a complication or recurrence of biliary symptoms after stent placement.

CONCLUSIONS

Endoscopic stent placement in the gallbladder is a safe and an effective palliative treatment for patients with symptoms caused by gallbladder disease who are poor surgical candidates.

Factors influencing the prevalence of gallstones in liver disease: the beneficial and harmful influences of alcohol

OBJECTIVE

The Patient Treatment File of the Department of Veterans Affairs comprises the computerized records of all inpatients treated in all Veterans Affairs hospitals distributed throughout the United States. This database was used to study the association between liver disease and clinically manifest cholelithiasis.

METHODS

The computerized medical records of 38,459 patients with various forms of liver disease and 69,336 controls without the diagnosis were extracted from the annual files between 1990 and 1993. In a multiple logistic regression analysis, the occurrence of cholelithiasis served as the outcome variable, whereas different forms of liver disease and demographic characteristics, such as age, gender, and ethnicity, served as predictor variables.

RESULTS

Among the control population, cholelithiasis was reported in 5.2% (3,571 of 69,336) of subjects. Cholelithiasis occurred in 7.5% (2,898 of 38,459) of patients with all liver disease, 9.5% (1,642 of 17,287) of patients with alcoholic liver cirrhosis, 13.7% (981 of 7,149) of patients with nonalcoholic liver cirrhosis, and 9.1% (66 of 728) of patients with alcoholic fatty liver (chi2 = 1059, df = 4, p < 0.001). In the logistic regression, the odds ratios (ORs) for cholelithiasis associated with various forms of liver disease were: in all liver diseases combined (OR = 1.31, 95% CI = 1.25-1.38), in alcoholic liver cirrhosis (OR = 1.62, 95% CI = 1.54-1.72), in nonalcoholic liver cirrhosis (OR = 2.07, 95% CI = 1.94-2.21), and in alcoholic fatty liver (OR = 1.40, 95% CI = 1.11-1.75). Other risk factors for cholelithiasis besides liver disease were: female gender (OR = 1.43, 95% CI = 1.25-1.63), older age (OR = 1.28 per age decade, 95% CI = 1.26-1.30), Native American (OR = 1.38, 95% CI = 1.12-1.72) or Hispanic ethnicity (OR = 1.25, 95% CI = 1.15-1.35), and presence of diabetes mellitus (OR = 1.43, 95% CI = 1.35-1.52). A history of alcoholism exerted a protective influence (OR = 0.92, 95% CI = 0.87-0.97).

CONCLUSION

Gallstone disease occurs frequently in hospitalized patients with chronic liver disease or liver cirrhosis and contributes to the burden of the disease.

Cholelithiasis in patients with Gaucher disease

Gaucher disease, the inherited deficiency of the lysosomal enzyme glucocerebrosidase, manifests with a continually expanding range of clinical features. Noting that a number of adult patients with type 1 Gaucher disease also had gallstones, we reviewed the clinical records of 66 adult patients evaluated at the National Institutes of Health with type 1 Gaucher disease. Twenty-one patients were identified who had either gallstones or a history of cholecystectomy. Of the 21 patients, 6 were male. The age at which stones were noted ranged from 19 to 70 years (mean 39 years). Thirteen of the patients had a cholecystectomy performed. Several different factors may contribute to the development of gallstones in these patients, including anemia, prior splenectomy, and hepatic involvement. Eleven of the patients were found to have chronic anemia. Fifteen of the patients underwent splenectomy. An increased biliary excretion of glucosylceramide could also contribute to cholelithiasis. To determine whether our findings were specific to our referral population, the medical records of a second series of 80 adult patients of Ashkenazi Jewish ancestry with type 1 Gaucher disease followed in Northern Israel were reviewed. Sixteen of these patients (5 male, 11 female) were also noted to have gallstones. Thus, the frequency of gallbladder involvement in patients with Gaucher disease appears to be greater than previously appreciated.

Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery

Several studies have demonstrated increased morbidity and mortality in patients with cirrhosis undergoing anesthesia and surgery. Cirrhosis is a chronic liver disease, which may affect all body systems. The severity of the disease, assessed by the Child-Pugh classification, has a substantial effect on patient outcome. The extent of surgery and co-morbid conditions also have a major impact. In the past few years, changes have been made in the diagnosis, preoperative preparation, surgical and anesthetic management and perioperative care of patients with liver disease. The aim of this review is to examine whether these changes have resulted in improved perioperative outcomes.

Comorbid occurrence of liver and pancreas disease in United States military veterans

OBJECTIVE

The clinical epidemiology of the comorbidity between liver and pancreas disease is unknown. The Patient Treatment File of the Department of Veterans Affairs contains the computerized records of all inpatients treated in 172 Department of Veterans Affairs hospitals distributed throughout the United States. This large database offers a unique opportunity to study the epidemiology of liver-pancreas comorbidity (LPC).

METHODS

In a case-control study, 6,393 LPC cases were compared to 34,513 controls with alcoholic liver disease and liver cirrhosis alone and 68,038 controls without liver or pancreas disease. Multivariate logistic regression analysis was used to assess the joint influence of multiple risk factors on the occurrence of LPC.

RESULTS

LPC occurred in 15.6% of patients with alcoholic liver disease and liver cirrhosis identified in the Patient Treatment File between 1990 and 1993. Compared to controls with liver disease alone, LPC cases were characterized by younger age (odds ratio = 0.88 per age decade, CI = 0.86-0.90) and African American (2.33, 2.18-2.48) or Hispanic (1.24, 1.12-1.38) ethnicity. Compared to controls with neither liver nor pancreas disease, LPC cases were characterized by male gender (1.67, 1.28-2.17), African American (1.41, 1.32-1.50) or Hispanic (2.04, 1.82-2.30) ethnicity, more frequent history of alcoholism (29.5, 26.7-32.6), and being divorced (1.35, 1.26-1.44).

CONCLUSIONS

Comorbidity of liver and pancreas disease is relatively common in the veteran population. Such patients are more frequently divorced and of African American or Hispanic ethnicity, and present with a history of excessive alcoholism at a relatively young age.

Gallstones

This review summarizes the main advances made in the epidemiology, pathogenesis, and medical treatment of gallstone disease in the past year. Whether rapid weight reduction can precipitate gallstone formation is still debated. Phospholipase A(2)-II seems to play an interesting role in the pathogenesis of multiple cholesterol stone formation, and ursodeoxycholic acid may partially halt the formation of multiple cholesterol stones by mediating an anti-inflammatory effect on the gallbladder. Bacterial infections may contribute to gallstone formation, perhaps through secretion of biofilm. The combination of ursodeoxycholic acid and simvastatin for the resolution and prevention of gallstones is promising, but larger studies are needed.